Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Metoprolol
Drug ID BADD_D01445
Description Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative.[T274] To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US.[A175162] Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978.[L5527]
Indications and Usage Metoprolol is indicated for the treatment of angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension.[A175141] Some off-label uses of metoprolol include supraventricular tachycardia and thyroid storm.[A175141] All the indications of metoprolol are part of cardiovascular diseases. These conditions correspond to a number of diseases that involve the function of the heart and blood vessels. The underlying causes of these conditions are variable and can be due to genetic disposition, lifestyle decisions such as smoking, obesity, diet, and lack of exercise, and comorbidity with other conditions such as diabetes. The cardiovascular diseases are the leading cause of death on a global scale.[L5533]
Marketing Status approved; investigational
ATC Code C07AB02
DrugBank ID DB00264
KEGG ID D02358
MeSH ID D008790
PubChem ID 4171
TTD Drug ID D0I2MK
NDC Product Code 70518-3506; 46708-292; 62207-970; 62332-113; 46708-290; 0615-8422; 0615-8423; 46708-291; 62332-114; 62332-112; 71205-003; 0615-8421; 65977-0117
UNII GEB06NHM23
Synonyms Metoprolol | Toprol | Betaloc | Betaloc-Astra | Betaloc Astra | Betalok | CGP-2175 | CGP 2175 | CGP2175 | H 93-26 | H 93 26 | H 9326 | Metoprolol Tartrate | Seloken | Spesicor | Spesikor | Metoprolol Succinate | Metoprolol CR-XL | Metoprolol CR XL | Toprol-XL | Toprol XL | Beloc-Duriles | Beloc Duriles | Lopressor
Chemical Information
Molecular Formula C15H25NO3
CAS Registry Number 51384-51-1
SMILES CC(C)NCC(COC1=CC=C(C=C1)CCOC)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Preterm premature rupture of membranes18.02.02.0160.000007%Not Available
Unmasking of previously unidentified disease08.01.03.0800.000010%Not Available
Pharyngeal paraesthesia22.04.05.018; 17.02.06.035--Not Available
Systolic anterior motion of mitral valve02.07.01.0100.000027%Not Available
Paroxysmal atrioventricular block02.03.01.0220.000010%Not Available
Blood loss anaemia24.07.01.088; 01.03.02.0180.000007%Not Available
BRASH syndrome14.05.03.005; 02.03.02.0300.000217%Not Available
Bundle branch block bilateral02.03.01.0250.000007%Not Available
Cardiac valve thickening02.07.02.0120.000007%Not Available
Cardiomyopathy neonatal18.04.07.011; 02.04.01.0160.000007%Not Available
Dilated cardiomyopathy02.04.01.0170.000017%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.000080%Not Available
Drug-disease interaction08.06.03.0120.000007%Not Available
Foetal renal impairment20.01.03.029; 18.03.02.0220.000007%Not Available
Hypertensive urgency24.08.01.0050.000007%Not Available
Implant site discharge12.07.02.037; 08.02.02.0370.000007%Not Available
Intermenstrual bleeding21.01.01.0150.000013%Not Available
Intra-abdominal fluid collection21.07.04.014; 07.07.01.0140.000007%Not Available
Myelosuppression01.03.03.0150.000013%Not Available
Pharyngeal swelling22.04.05.0280.000007%Not Available
Potentiating drug interaction08.06.03.0150.000010%Not Available
Reaction to excipient10.01.01.0420.000015%Not Available
Suspected suicide08.04.01.017; 19.12.01.0090.000027%Not Available
Therapeutic product effect variable08.06.01.0550.000007%Not Available
Therapy non-responder08.06.01.0630.000068%Not Available
Therapy partial responder08.06.01.0640.000010%Not Available
Pleural calcification22.05.03.009--Not Available
The 17th Page    First    Pre   17    Total 17 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene